Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AcelRx Pharmaceuticals, Inc. ACRX
$0.77
-$0.02 (-2.03%)
На 18:00, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
8262048.00000000
-
week52high
7.60
-
week52low
0.55
-
Revenue
1771000
-
P/E TTM
0
-
Beta
0.24463600
-
EPS
5.60000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Buy | 14 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 авг 2021 г. |
| Credit Suisse | Underperform | Underperform | 13 авг 2020 г. |
| Credit Suisse | Underperform | Neutral | 20 июл 2020 г. |
| H.C. Wainwright | Buy | Buy | 17 мар 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bozilenko Marina | A | 31000 | 31000 | 15 июл 2022 г. |
| Bozilenko Marina | A | 40500 | 15500 | 15 июл 2022 г. |
| Broadfoot Jill Marie | A | 31000 | 31000 | 15 июл 2022 г. |
| Broadfoot Jill Marie | A | 30500 | 15500 | 15 июл 2022 г. |
| Afable Richard | A | 31000 | 31000 | 15 июл 2022 г. |
| Afable Richard | A | 37750 | 15500 | 15 июл 2022 г. |
| ADAMS ADRIAN | A | 31000 | 31000 | 15 июл 2022 г. |
| ADAMS ADRIAN | A | 211750 | 15500 | 15 июл 2022 г. |
| Rosen Howard B | A | 31000 | 31000 | 15 июл 2022 г. |
| Rosen Howard B | A | 94250 | 15500 | 15 июл 2022 г. |
Новостная лента
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
Zacks Investment Research
10 мая 2023 г. в 19:45
AcelRx Pharmaceuticals (ACRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $1.20 per share a year ago.
AcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call Transcript
Seeking Alpha
30 мар 2023 г. в 20:28
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Welcome to the AcelRx 2022 Full Year and Fourth Quarter Financial Results Conference Call. This call is being webcast live via the Events page on the Investors section of AcelRx's website at www.acelrx.com.
AcelRx Pharmaceuticals (ACRX) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
30 мар 2023 г. в 20:01
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
PRNewsWire
21 мар 2023 г. в 16:05
HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release full year and fourth quarter financial results for 2022 after the market close on Thursday, March 30, 2023.
AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 23:09
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2022 Results Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - Chief Executive Officer Pamela Palmer - Chief Medical Officer and Co-Founder Conference Call Participants Brandon Folkes - Cantor Fitzgerald Thomas Lee - HC Wainwright & Company Operator Welcome to the AcelRx Third Quarter 2022 Earnings Call. This call is being webcast live via the Events page of the Investors section of AcelRx's website at www.acelrx.com.